Cargando…
Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy
The underlying molecular mechanisms of adverse drug events (ADEs) associated with cancer therapy drugs may overlap with their antineoplastic mechanisms. In a previous study, we developed an ADE-based tumor stratification framework (known as ADEStrata) with a case study of breast cancer patients rece...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Informatics Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525249/ https://www.ncbi.nlm.nih.gov/pubmed/26306234 |
_version_ | 1782384300958679040 |
---|---|
author | Wang, Chen Zimmermann, Michael T. Chute, Christopher G. Jiang, Guoqian |
author_facet | Wang, Chen Zimmermann, Michael T. Chute, Christopher G. Jiang, Guoqian |
author_sort | Wang, Chen |
collection | PubMed |
description | The underlying molecular mechanisms of adverse drug events (ADEs) associated with cancer therapy drugs may overlap with their antineoplastic mechanisms. In a previous study, we developed an ADE-based tumor stratification framework (known as ADEStrata) with a case study of breast cancer patients receiving aromatase inhibitors, and demonstrated that the prediction of per-patient ADE propensity simultaneously identifies high-risk patients experiencing poor outcomes. In this study, we aim to evaluate the ADEStrata framework with a different tumor type and chemotherapy class – ovarian cancer treated with platinum chemotherapeutic drugs. We identified a cohort of ovarian cancer patients receiving cisplatin (a standard platinum therapy) from The Cancer Genome Atlas (TCGA) (n=156). We demonstrated that somatic variant prioritization guided by known ADEs associated with cisplatin could be used to stratify patients treated with cisplatin and uncover tumor subtypes with different clinical outcomes. |
format | Online Article Text |
id | pubmed-4525249 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | American Medical Informatics Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-45252492015-08-24 Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy Wang, Chen Zimmermann, Michael T. Chute, Christopher G. Jiang, Guoqian AMIA Jt Summits Transl Sci Proc Articles The underlying molecular mechanisms of adverse drug events (ADEs) associated with cancer therapy drugs may overlap with their antineoplastic mechanisms. In a previous study, we developed an ADE-based tumor stratification framework (known as ADEStrata) with a case study of breast cancer patients receiving aromatase inhibitors, and demonstrated that the prediction of per-patient ADE propensity simultaneously identifies high-risk patients experiencing poor outcomes. In this study, we aim to evaluate the ADEStrata framework with a different tumor type and chemotherapy class – ovarian cancer treated with platinum chemotherapeutic drugs. We identified a cohort of ovarian cancer patients receiving cisplatin (a standard platinum therapy) from The Cancer Genome Atlas (TCGA) (n=156). We demonstrated that somatic variant prioritization guided by known ADEs associated with cisplatin could be used to stratify patients treated with cisplatin and uncover tumor subtypes with different clinical outcomes. American Medical Informatics Association 2015-03-23 /pmc/articles/PMC4525249/ /pubmed/26306234 Text en ©2015 AMIA - All rights reserved. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose |
spellingShingle | Articles Wang, Chen Zimmermann, Michael T. Chute, Christopher G. Jiang, Guoqian Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title | Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title_full | Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title_fullStr | Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title_full_unstemmed | Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title_short | Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy |
title_sort | adverse drug events-based tumor stratification for ovarian cancer patients receiving platinum therapy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525249/ https://www.ncbi.nlm.nih.gov/pubmed/26306234 |
work_keys_str_mv | AT wangchen adversedrugeventsbasedtumorstratificationforovariancancerpatientsreceivingplatinumtherapy AT zimmermannmichaelt adversedrugeventsbasedtumorstratificationforovariancancerpatientsreceivingplatinumtherapy AT chutechristopherg adversedrugeventsbasedtumorstratificationforovariancancerpatientsreceivingplatinumtherapy AT jiangguoqian adversedrugeventsbasedtumorstratificationforovariancancerpatientsreceivingplatinumtherapy |